autolog bone marrow transplant multipl myeloma identif prognost factor multipl myeloma fatal malign median surviv time year clinic trial feasibl efficaci marrow-abl chemoradiotherapi unpurg autolog bone marrow abmt prognost variabl total bodi irradi melphalan thiotepa patient median age year year group patient resist melphalan-prednison continu infus vincristin adriamycin high dose dexamethason vad primari unrespons diseas resist relaps patient remiss vad regimen first subsequ remiss cytoreduct equal patient refractori myeloma cytoreduct magnitud patient remiss vad earli death patient patient resist relaps none complet remiss group median durat relapse-fre overal surviv month patient earli death complet remiss incid patient first remiss surviv rate regardless diseas statu remiss primari resist inform sensit therapi unavail presenc abmt high level mg/l non-igg isotyp patient poor prognosi respond month patient month contrast project surviv rate patient seri investig novel treatment approach comparison standard dose regimen result marrow-abl therapi myeloma patient resist relaps combin risk factor advanc tumor burden absenc igg isotyp appar lack advers effect plasmacytosi autograft need cytoreduct marrow purg 